Posted on 12/12/16
Better Buy: Amgen Inc. vs. Biogen
Two of the biggest biotechs in the world haven't exactly had a great 2016. Shares of Amgen(NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) are both down year to date. . . .
Posted on 12/9/16
The 3 Best Biotech Stocks for 2017
Trying to pick the best biotech stocks for 2017 -- defined as those with the best returns -- is a bit of a crapshoot. The biotech . . .
Posted on 12/9/16
Pfizer (PFE) Management Presents at Citi Global Healthcare Conference (Transcript)
Call Start: 14:10Call End: 14:48Pfizer Inc. (NYSE:PFE)Citi Global Healthcare Conference CallDecember 8, 2016 14:10 ETExecutivesMikael Dolsten - President, R&DAnalystsAndrew Baum - CitiAndrew BaumAll right, I have . . .
Posted on 12/9/16
Better Buy: Johnson & Johnson vs. Pfizer Inc.
Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) have several things in common. They're two of the biggest drugmakers in the world. The stocks are popular among . . .
Posted on 12/9/16
Early Stage Digital Health Companies In Philadelphia Get Boost With $6 Million Funding Initiative
Partnering to fuel Philadelphia's innovative digital health ecosystem, Ben Franklin Technology Partners of Southeastern Pennsylvania; Independence Health Group, the parent company of Independence Blue Cross; and . . .
Posted on 12/9/16
PANTHERx Specialty Pharmacy Ranks #1 in Patient Satisfaction
PANTHERx Specialty Pharmacy was recently ranked #1 in the Zitter Health Insights Patient Satisfaction Survey for Q3 2016. PANTHERx received one of the highest scores ever . . .
Posted on 12/8/16
Sanofi and Johnson & Johnson May Battle for the Right to Overpay for Actelion
IMAGE SOURCE: GETTY IMAGES.Who said mergers and acquisitions (M&A) were slowing down in the drug industry? Certainly not healthcare conglomerate Johnson & Johnson (NYSE:JNJ), which has . . .
Posted on 12/8/16
Why You Should (and Shouldn't) Buy Celldex Therapeutics, Inc.
President-elect Trump's pledge to ease corporate taxes on repatriated capital stashed overseas has the market buzzing over Celldex Therapeutics (NASDAQ:CLDX) and other small-cap biotechs.IMAGE SOURCE: GETTY . . .
Posted on 12/8/16
Why Celldex Rallied 22% In November
IMAGE SOURCE: GETTY IMAGES.What happenedAfter announcing the acquisition of the privately held Kolltan and reporting third-quarter financials, shares in Celldex Therapeutics (NASDAQ:CLDX) jumped 22% last month, . . .
Posted on 12/8/16
Better Buy: Amgen Inc. vs. Pfizer
IMAGE SOURCE: GETTY IMAGES.Over the past five years, Amgen (NASDAQ:AMGN) investors have enjoyed a market-thumping 166.1% gain. During the same period, Pfizer (NYSE:PFE) shares rose just . . .
Posted on 12/8/16
Is Pfizer's New PD-L1 Drug a Game-Changer?
The Food and Drug Administration has agreed to review Pfizer Inc.'s (NYSE:PFE) PD-L1 checkpoint inhibitor, avelumab, under an accelerated approval pathway. If it's given the go-ahead, . . .
Posted on 12/8/16
Better Buy: Johnson & Johnson vs. Eli Lilly
Just ahead of the Thanksgiving holiday, Eli Lilly (NYSE:LLY) announced the third late-stage clinical failure for its Alzheimer's disease candidate. The stock had given up some . . .
Posted on 12/7/16
Zoetis Announces Authorization of $1.5 Billion Share Repurchase Program
ARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that its Board of Directors has authorized a $1.5 billion multi-year share repurchase program as part of its . . .
Posted on 12/6/16
J&J Target Offers Over 20% Upside
Welcome to the No More Tears issue of M&A DailyJohnson & JohnsonActelion (OTCPK:ALIOY) rejected the initial offer from J&J (NYSE:JNJ) but will be more receptive to . . .
Posted on 12/6/16
Novartis Makes Its Case For Driving A CAR Into The Real World
Rather like Kite’s (NASDAQ:KITE) registrational Zuma-1 trial of KTE-C19 in lymphoma, Novartis’ (NYSE:NVS) Eliana study has generated a fileable response rate. In the case of the . . .
Posted on 12/6/16
Biotech's Dumbest CEO Moves in 2016
IMAGE SOURCE: GETTY IMAGES.Investing in biotech companies isn't easy, but it seems likely that leading them is even harder. Ultimately the destiny of the company is . . .
Posted on 12/6/16
Why PTC Therapeutics, Inc. Stock Rose 75.4% in November
IMAGE SOURCE: GETTY IMAGES.What happenedShares of small-cap biotech PTC Therapeutics, Inc. (NASDAQ:PTCT) flew 75.4% upward in November, according to data from S&P Global Market Intelligence. An . . .
Posted on 12/6/16
Why Celgene Shares Jumped 13.9% In November
IMAGE SOURCE: GETTY IMAGES.What happenedFollowing the election of Donald Trump as the next U.S. president and ahead of intriguing early stage data out of one of . . .
Posted on 12/6/16
Read This Before You Buy Biotech Stocks
Plenty of growth investors flock to biotech stocks because the industry can provide eye-popping gains. For example, shares of Tesaro (NASDAQ:TSRO) more than doubled after the . . .
Posted on 12/6/16
Ogilvy CommonHealth Worldwide Wins Silver At 2016 Clio Health Awards
Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP company (NASDAQ: WPPGY) (www.wpp.com), today announced the organization's Sydney-based . . .
Posted on 12/5/16
Forget Pfizer: Here Are 3 Better Dividend Stocks
When people think dividend stocks, Pfizer (NYSE:PFE) is sure to be high on the list. After all, the massive pharma stock pays out 3.75% annually, solidly . . .
Posted on 12/5/16
Does Pfizer Pass Warren Buffett’s Test?
Warren Buffett has a long and storied history of using Berkshire Hathaway's financial might to make earth-shattering acquisitions. Over the years he has spent tens of . . .
Posted on 12/5/16
This Trump Appointment Likely Spells Imminent Doom for Obamacare
IMAGE SOURCE: GETTY IMAGES.The Affordable Care Act as we know it could be on its last legs.The ACA, which is more commonly known as Obamacare, transformed . . .
Posted on 12/4/16
Retro Fitness Expands Florida Footprint through Franchising
COLTS NECK, N.J.--(BUSINESS WIRE)--Retro Fitness, a fast-growing, national low-cost, high-value fitness franchise, is targeting the Sunshine State for significant expansion. With six franchise locations already open . . .
Posted on 12/1/16
The Wistar Institute Awarded Nearly $9 Million to Advance Synthetic DNA Antibody-Based Therapy to Protect Against Zika Virus
The Wistar Institute is pleased to announce the Bill & Melinda Gates Foundation has awarded an $8,777,578 million grant to The Wistar Institute to create a . . .
Philadelphia
